Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort

By sjmartinez • April 10, 2025

Davies Smith E, Malvestutto C, Ribaudo HJ, Fichtenbaum CJ, Aberg JA, Watanabe M, Bloomfield GS, Currier JS, Chu SM, Fitch KV, Diggs MR, Bedimo R, Valencia J, Gomez-Ayerbe C, Brar I, Madruga JV, Lu MT, Douglas PS, Zanni MV, Grinspoon SK. Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort. Open Forum Infect Dis. 2025 Mar 21;12(4):ofaf177. doi: 10.1093/ofid/ofaf177. PMID: 40207047; PMCID: PMC11979587.

Tags: abacavir, antiretroviral therapy, Infectious Diseases, major adverse cardiovascular events, Publications, REPRIEVE, Tenofovir

Impact of changing pre-exposure prophylaxis regimens on retention among men who have sex with men in Hanoi, Vietnam (2020-2023): a cohort study

Setrakian N, Bui HTM, Adamson PC, Hoang TN, Gorbach PM, Giang LM. Impact of changing pre-exposure prophylaxis regimens on retention among men who have sex[...]

PrEP preferences and early acceptability of injectable cabotegravir among pregnant and lactating people in Cape Town, South Africa: findings from the PrEPared to Choose study

Wara N, Pike C, Rousseau E, Macdonald P, Mapukata P, Leonard B, Lebelo K, Hoffman R, Orrell C, Bekker LG, Davey DJ. PrEP preferences and[...]

Adhesin Als4112 promotes Candida auris skin colonization through interactions with keratinocytes and extracellular matrix proteins

Zhao G, Lyu J, Veniaminova NA, Zarnowski R, Mattos E, Johnson CJ, Quintanilla D, Hautau H, Hold LA, Xu B, Anku JAE, Dasgupta K, Hale[...]